Clinical trial registry record

A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 1 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated November 21, 2019.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT01518920
Last registry update
November 21, 2019
Status
Completed
Phase
Phase 1
Sponsor
Biogen
Enrollment
44
Countries
United States
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1
Study design
RANDOMIZED · CROSSOVER · TREATMENT · TRIPLE
Evidence population
Human clinical study registration
Participants
44
Population
ALL · 50 Years to 75 Years
Duration
2011-12-01 to 2013-02-01
Intervention
PF-04958242; Placebo
Comparator
Placebo
Outcomes measured
Change from baseline to 1 hour post-dose in pure tone audiometry averaged over 2 and 4 kHz — 1 hour; Change from baseline to 5 hours post-dose in pure tone audiometry averaged over 2 and 4 kHz — 5 hours; Change from baseline to 1 hr and 5 hrs post-dose in Speech Discrimination Score — 1 hour, 5 hours; Change from baseline to 1 hr and 5 hrs post dose in Speech In Noise Testing — 1 hour, 5 hours; Change from baseline to 1 hr and 5 hrs post dose in Tinnitus Severity Ranking Scale — 1 hour, 5 hours; Plasma PF 04958242 concentrations at 45 min post dose and following endpoint assessments at 1 and 5 hrs post dose. — 45…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Hearing ageing · 100%Title contains controlled term: age-related hearing loss. Abstract contains controlled term: age-related hearing loss. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

hearing aging
Open primary sourceExport JSON